163 related articles for article (PubMed ID: 34249442)
1. Epigenetic heterogeneity promotes acquired resistance to BET bromodomain inhibition in ovarian cancer.
Sun Y; Zhang Z; Zhang K; Liu Y; Shen P; Cai M; Jia C; Wang W; Gu Z; Ma P; Lu H; Guan L; Di W; Zhuang G; Yin X
Am J Cancer Res; 2021; 11(6):3021-3038. PubMed ID: 34249442
[TBL] [Abstract][Full Text] [Related]
2. Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4.
Calder J; Nagelberg A; Luu J; Lu D; Lockwood WW
Oncogenesis; 2021 Mar; 10(3):27. PubMed ID: 33712563
[TBL] [Abstract][Full Text] [Related]
3. Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.
Kurimchak AM; Shelton C; Duncan KE; Johnson KJ; Brown J; O'Brien S; Gabbasov R; Fink LS; Li Y; Lounsbury N; Abou-Gharbia M; Childers WE; Connolly DC; Chernoff J; Peterson JR; Duncan JS
Cell Rep; 2016 Aug; 16(5):1273-1286. PubMed ID: 27452461
[TBL] [Abstract][Full Text] [Related]
4. Bromodomain-Containing Protein BRD4 Is Hyperphosphorylated in Mitosis.
Wang R; Yang JF; Ho F; Robertson ES; You J
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32575711
[TBL] [Abstract][Full Text] [Related]
5. Concurrent targeting of MAP3K3 and BRD4 by
Liu C; Gen Y; Tanimoto K; Muramatsu T; Inoue J; Inazawa J
Mol Ther Nucleic Acids; 2021 Sep; 25():83-92. PubMed ID: 34258104
[TBL] [Abstract][Full Text] [Related]
6. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
8. Vitamin C Sensitizes Melanoma to BET Inhibitors.
Mustafi S; Camarena V; Volmar CH; Huff TC; Sant DW; Brothers SP; Liu ZJ; Wahlestedt C; Wang G
Cancer Res; 2018 Jan; 78(2):572-583. PubMed ID: 29180474
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer.
Kurimchak AM; Shelton C; Herrera-Montávez C; Duncan KE; Chernoff J; Duncan JS
Mol Cancer Res; 2019 Aug; 17(8):1721-1734. PubMed ID: 31043489
[TBL] [Abstract][Full Text] [Related]
10. Clinical perspectives of BET inhibition in ovarian cancer.
Andrikopoulou A; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F
Cell Oncol (Dordr); 2021 Apr; 44(2):237-249. PubMed ID: 33469840
[TBL] [Abstract][Full Text] [Related]
11. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
12. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
[TBL] [Abstract][Full Text] [Related]
13. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
[TBL] [Abstract][Full Text] [Related]
14. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
J Virol; 2018 May; 92(10):. PubMed ID: 29343578
[TBL] [Abstract][Full Text] [Related]
15. Co-inhibition of BET proteins and PD-L1 as a potential therapy for OSCC through synergistic inhibition of FOXM1 and PD-L1 expressions.
Wang W; Tan J
J Oral Pathol Med; 2019 Oct; 48(9):817-825. PubMed ID: 31177574
[TBL] [Abstract][Full Text] [Related]
16. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
[No Abstract] [Full Text] [Related]
17. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer.
Coleman DJ; Gao L; Schwartzman J; Korkola JE; Sampson D; Derrick DS; Urrutia J; Balter A; Burchard J; King CJ; Chiotti KE; Heiser LM; Alumkal JJ
Sci Rep; 2019 Mar; 9(1):3823. PubMed ID: 30846826
[TBL] [Abstract][Full Text] [Related]
19. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W
Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]